Success Metrics

Clinical Success Rate
89.0%

Based on 186 completed trials

Completion Rate
89%(186/209)
Active Trials
91(22%)
Results Posted
10%(19 trials)
Terminated
23(6%)

Phase Distribution

Ph early_phase_1
2
0%
Ph not_applicable
40
10%
Ph phase_1
2
0%
Ph phase_2
28
7%
Ph phase_3
31
8%
Ph phase_4
2
0%

Phase Distribution

4

Early Stage

28

Mid Stage

33

Late Stage

Phase Distribution105 total trials
Early Phase 1First-in-human
2(1.9%)
Phase 1Safety & dosage
2(1.9%)
Phase 2Efficacy & side effects
28(26.7%)
Phase 3Large-scale testing
31(29.5%)
Phase 4Post-market surveillance
2(1.9%)
N/ANon-phased studies
40(38.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.3%

186 of 213 finished

Non-Completion Rate

12.7%

27 ended early

Currently Active

91

trials recruiting

Total Trials

405

all time

Status Distribution
Active(121)
Completed(186)
Terminated(27)
Other(71)

Detailed Status

Completed186
Recruiting73
unknown69
Not yet recruiting26
Terminated23
Active, not recruiting18

Development Timeline

Analytics

Development Status

Total Trials
405
Active
91
Success Rate
89.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.9%)
Phase 12 (1.9%)
Phase 228 (26.7%)
Phase 331 (29.5%)
Phase 42 (1.9%)
N/A40 (38.1%)

Trials by Status

not_yet_recruiting266%
withdrawn41%
active_not_recruiting184%
enrolling_by_invitation41%
suspended20%
recruiting7318%
completed18646%
unknown6917%
terminated236%

Recent Activity

Clinical Trials (405)

Showing 20 of 405 trialsScroll for more
NCT07723599

Combating Age-related Failure of Myelination in Multiple Sclerosis: An Exploratory Study

Not Yet Recruiting
NCT07718802Not Applicable

Observational Approach Versus Surgical Intervention for Stones

Not Yet Recruiting
NCT05377372Not Applicable

Early Life Exposures Among Children With Sickle Cell Disease

Recruiting
NCT05640999Phase 2

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Recruiting
NCT07533890Not Applicable

Fecal Microbiome Signature of Multi-Strain Probiotics Supplementation in Children and Adolescents With Inflammatory Bowel Disease

Recruiting
NCT05810493

A Cohort of Patients With Phenotyped Diffuse Interstitial Lung Disease With Longitudinal Follow-up

Completed
NCT00165256Phase 2

Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast

Completed
NCT04566432

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Completed
NCT06665399

Observation Alone for Mild Non-Lactational Mastitis

Completed
NCT07654465Phase 2

Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma

Not Yet Recruiting
NCT05257551

Tempus Small Cell Lung Cancer Observational Study (Sculptor)

Recruiting
NCT07645976

Home Environmental Risks and Caregiver Awareness

Completed
NCT04388943

Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study)

Recruiting
NCT07513324Phase 2

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Not Yet Recruiting
NCT07610356

Predictors of Transmural Non-Occlusive Mesenteric Ischemia in ICU Patients With Suspected Acute Mesenteric Ischemia

Recruiting
NCT03414151

Gut Microbiome in AP Naive

Active Not Recruiting
NCT05976347Phase 4

Identifying and Treating Depression in the Orthopaedic Trauma Population

Recruiting
NCT05119387

Genetic Study of Amyotrophic Lateral Sclerosis in Norway

Recruiting
NCT07596524

Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy

Not Yet Recruiting
NCT05255653Phase 2

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
405